Korro Bio (NASDAQ:KRRO – Get Free Report) and Compass Therapeutics (NASDAQ:CMPX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Insider & Institutional Ownership
13.2% of Korro Bio shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Korro Bio has a beta of 3.13, suggesting that its stock price is 213% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Valuation and Earnings
This table compares Korro Bio and Compass Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Korro Bio | $6.39 million | 27.71 | -$117.26 million | ($10.00) | -1.20 |
| Compass Therapeutics | $850,000.00 | 158.31 | -$66.49 million | ($0.40) | -1.87 |
Compass Therapeutics has lower revenue, but higher earnings than Korro Bio. Compass Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Korro Bio and Compass Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Korro Bio | N/A | -114.26% | -68.57% |
| Compass Therapeutics | N/A | -38.71% | -34.72% |
Analyst Recommendations
This is a breakdown of current recommendations for Korro Bio and Compass Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
| Compass Therapeutics | 1 | 3 | 12 | 1 | 2.76 |
Korro Bio presently has a consensus price target of $16.50, suggesting a potential upside of 37.27%. Compass Therapeutics has a consensus price target of $10.25, suggesting a potential upside of 1,271.79%. Given Compass Therapeutics’ higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Korro Bio.
Summary
Compass Therapeutics beats Korro Bio on 9 of the 13 factors compared between the two stocks.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
